ALMOND THERAPY: TARGETING THE AMYGDALA
DEAD

Serial Number

97182740

Owner

PsiloTec Health Solutions Inc.

Attorney

Charles G. Zug

Filing Date

Dec 21, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ALMOND THERAPY: TARGETING THE AMYGDALA Trademark

Serial Number: 97182740

ALMOND THERAPY: TARGETING THE AMYGDALA is a trademark filed by PsiloTec Health Solutions Inc. on December 21, 2021. The trademark is classified under Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

PsiloTec Health Solutions Inc. (2 trademarks)

Suite 3500
Calgary, Alberta T2P4J8 , CA

Entity Type: 03

Trademark Details

Filing Date

December 21, 2021

Registration Date

Not Registered

Goods & Services

Compilation for business purposes and processing of medical data relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes

Medical and scientific research and development in the field of psychedelics; medical and scientific research in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; laboratory research in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; providing temporary use of online, non-downloadable computer software for providing therapy services in the nature of scheduling and facilitating Internet-based patient and medical provider meetings to individuals in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; compilation of medical data for research purposes relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes

Psychotherapy services; mental health therapy for the treatment of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; provision of information to others in the field of mental health; clinical mental health counselling services

Provision of education in the nature of providing courses of instruction and training in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; provision of education in the nature of providing courses of instruction and training in the field of psychedelic medicines

Compilation of medical data for financial purposes relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jun 29, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 29, 2026 ABN2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 15, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 15, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 15, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 14, 2026 RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 14, 2025 RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 10, 2025 RCCK
ASSIGNED TO EXAMINER
Nov 30, 2024 DOCK
ASSIGNED TO EXAMINER
Nov 30, 2024 DOCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 24, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 24, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jul 24, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 20, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 20, 2024 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 20, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 22, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 22, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 22, 2024 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 24, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 24, 2023 GNSL
SUSPENSION LETTER WRITTEN
Oct 24, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 23, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 23, 2023 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 23, 2023 CHAN
ASSIGNED TO LIE
Oct 22, 2023 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 23, 2023 ERSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 23, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 23, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 23, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 23, 2023 REAP
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 23, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 23, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 23, 2023 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 25, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 25, 2022 GNSL
SUSPENSION LETTER WRITTEN
Aug 25, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 24, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 24, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 24, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 28, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jun 28, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jun 28, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 24, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 28, 2021 NWOS
NEW APPLICATION ENTERED
Dec 24, 2021 NWAP